PWM
MYGN icon

Paulson Wealth Management’s Myriad Genetics MYGN Stock Holding History

Paulson Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-63
Closed -$2K – 369
2017
Q4 		$2K Buy
+63
New +$2.13K ﹤0.01% 554

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Paulson Wealth Management's MYGN Position: Q1 2018 in Review

Paulson Wealth Management sold out of Myriad Genetics (MYGN) in Q1 2018, closing a stake of 63 shares — an estimated $2K sold.

Paulson Wealth Management first reported a position in MYGN in Q4 2017 and held it in 1 quarter. The position peaked at $2K in Q4 2017. 260 funds tracked by Wall St. Rank hold MYGN as of Q1 2018.

  • Paulson Wealth Management reported no remaining Myriad Genetics position as of Q1 2018 after selling out during the quarter.
  • Paulson Wealth Management sold 63 Myriad Genetics shares in Q1 2018, an estimated $2K.
  • Paulson Wealth Management first reported a position in Myriad Genetics in Q4 2017 and held it in 1 quarter.
  • Paulson Wealth Management's Myriad Genetics position peaked at $2K in Q4 2017.
  • 260 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2018.

Based on Paulson Wealth Management's 13F filing for Q1 2018, filed 2 May 2018.